6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity.
- 1 September 1996
- Vol. 39 (3) , 401-406
- https://doi.org/10.1136/gut.39.3.401
Abstract
6-Mercaptopurine (6-MP) has confirmed short and longterm efficacy in the treatment of IBD. However, the relation between its metabolism, efficacy, and side effects is not well understood. To assay 6-MP metabolites and to correlate levels with drug compliance, disease activity, and adverse effects of treatment. Heparinised blood was obtained prior to daily administration of 6-MP in 25 adolescent Crohn's disease patients (14 ileocolitis, 11 colitis) receiving 1.2 (range 0.4-1.6) mg/kg/day for a mean of 17 (range 4-65) months. Erythrocyte free bases 6-thioguanine (6-TG) and 6-methyl-mercaptopurine (6-MMP) were measured (pmol/8 x 10(8) red blood cells) using reverse phase high performance liquid chromatography. Disease activity (modified Harvey-Bradshaw index) improved significantly with 6-MP (p = 0.001). Clinical remission was achieved in 72% of patients, who stopped taking prednisone, or were successfully weaned to a low alternate day dose (< 0.4 mg/kg/OD). Remission correlated well with erythrocyte 6-TG (p < 0.05), but not 6-MMP levels. Neutropenia was associated with 6-MP use (p < 0.005), but did not correlate with erythrocyte 6-MP metabolite levels. One patient refractory to 6-MP had 6-TG, but no measureable 6-MMP production, suggesting deficient thiopurine methyl-transferase activity or poor compliance. 6-MP induced complications (hepatitis, pancreatitis, and marrow suppression) were generally associated with increased 6-MMP levels. These results suggest that high performance liquid chromatography measurement of erythrocyte 6-MP metabolites may provide a quantitative assessment of patient responsiveness and compliance to treatment. The data support an immunosuppressive role for 6-TG, and potential cytotoxicity of raised 6-MMP levels.Keywords
This publication has 32 references indexed in Scilit:
- 6-mercaptopurine (6-MP) metabolite measurement in IBD patients' neutrophils correlates with drug efficacy: ∗, E. Seidman∗, Y. Théorêt†. Division of Gastroenterology, Dept. of Pediatrics∗, and Dept. of Pharmacology†, Centre de Recherche, Hôpital Ste-Justine, Université de Montréal, Montreal, CanadaGastroenterology, 1995
- Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia.Archives of Disease in Childhood, 1993
- Reversal of 6-mercaptopurine and 6-methylmercaptopurine ribonucleoside cytotoxicity by amidoimidazole carboxamide ribonucleoside in Molt F4 human malignant T-lymphoblastsBiochemical Pharmacology, 1993
- 6-Mercaptopurine: Cytotoxicity and biochemical pharmacology in human malignant T-lymphoblastsBiochemical Pharmacology, 1993
- Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemiaThe Journal of Pediatrics, 1991
- 6-Mercaptopurine Therapy in Selected Cases of Corticosteroid-Dependent Crohn's DiseaseMayo Clinic Proceedings, 1991
- Immunology of Inflammatory Bowel DiseaseJournal of Pediatric Gastroenterology and Nutrition, 1991
- Azathioprine in the treatment of children with inflammatory bowel diseaseThe Journal of Pediatrics, 1990
- Variable Bioavailability of Oral MercaptopurineNew England Journal of Medicine, 1983
- A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITYThe Lancet, 1980